Key Points
-
CEO Leon Moulder acquired 60,000 shares for a total value of approximately $1.01 million on May 18, 2026.
-
This transaction represents 13.04% of his aggregate holdings prior to the transaction.
-
The purchase is consistent with a pattern of net buying, reflecting ongoing accumulation capacity as holdings have expanded substantially over the past year.
Leon O. Molder Jr., Chief Executive Officer of Zenas BioPharma (NASDAQ:ZBIO)reported the open-market purchase of 60,000 shares at a weighted average price of $16.88 per share, according to the SEC Form 4 filing.
Transaction Summary
MetricValueShares traded60,000 Transaction value$1.0 million Post-transaction shares (direct)423,155 Post-transaction value (direct ownership)~$7.16 million
* Transaction value based on SEC Form 4 weighted average purchase price ($16.88). Post-transaction value based on May 18, 2026 closing price.
Key Questions
- How does this purchase compare to Leon Moulder’s historical trading activity?
This 60,000-share acquisition falls within the higher end of his transaction sizes over the past year, with several purchases in the 54,000, 60,000, 57,000, and 100,000 share range, supporting a sustained accumulation trend. - What is the impact on overall insider ownership?
Following this transaction, Moulder controls 423,155 directly-held shares, with total beneficial ownership, including shares held indirectly via the Leon O. Moulder, Jr. Revocable Trust, exceeding 520,000 shares, or approximately 0.95% of Zenas BioPharma’s outstanding shares as of the latest filing. He also holds another 1,786,039 shares indirectly through Tellus BioVentures LLC. - What is the market context for the purchase price?
The shares were acquired at a weighted average price of $16.88, with the stock showing a 53.6% one-year total return as of the transaction date. - Does the transaction reflect available capacity or a change inthinking>
Also Read